11630 SW 97 Street, Miami, Florida 33176, US

Advertising Driven Press Release Distribution

Tag: Gene Therapy

NeuExcell Therapeutics and Spark Therapeutics Announce Research Collaboration Agreement to Develop a Novel Gene Therapy for Huntington’s Disease

Press Release
Using NeuExcell’s neuroregenerative gene therapy platform, the collaboration aims to develop an effective and safe treatment for patients suffering from Huntington’s Disease. Spark Therapeutic’s excellence in R&D and proprietary adeno-associated virus (AAV) vector gene therapy platform may advance the development of the program and overcome hurdles and challenges of viral vectors for gene therapy. NeuExcell is eligible to receive upfront, license fees, R&D and Sales milestone payments up to approximately. Read More>>

NeuExcell Therapeutics names Russ Addis as Vice President, Research

Press Release
August 23, 2021. State College, Pennsylvania  – NeuExcell Therapeutics Inc. (www.neuexcell.com) today announced the appointment of Russ Addis, Ph.D. to the new position of Vice President, Research, effective immediately. Dr. Addis will report directly to Dr. Ronald HW Lorijn, Chief Executive Officer, and will oversee the Company’s gene therapy programs. Dr. Addis leads a growing organization and will build on the earlier activities and current expansion of the lab and. Read More>>

Increasing incidence of hematological and genetic disorders in both developed and developing countries fuels the demand for Adeno-Associated Virus (AAV) Vectors in Gene Therapy

Press Release
DelveInsight's Adeno-Associated Virus (AAV) Vectors in Gene Therapy Pipeline report provides in-depth analysis of the current clinical development landscape and growth prospects for Adeno-Associated Virus (AAV) Vectors in Gene Therapy. Some of the Crucial Highlights from the AAV Vectors in Gene Therapy Pipeline Report AAV particles are made up of single-stranded DNA encased in a protein shell. Despite their basic structure, recombinant AAVs (rAAV) can play a critical role in. Read More>>

The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predicts Roots Analysis

Press Release
With multiple approved products, the field of gene therapies has gained substantial momentum over the last couple of decades; innovator companies are gradually progressing their proprietary therapy candidates with cautious optimism Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”. The report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies,. Read More>>

The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predicts Roots Analysis

Press Release
With multiple approved products, the field of gene therapies has gained substantial momentum over the last couple of decades; innovator companies are gradually progressing their proprietary therapy candidates with cautious optimism Roots Analysis is pleased to announce the publication of its recent study, titled, “Gene Therapy Market (3rd Edition), 2019-2030”. The report features an extensive study of the current market landscape of gene therapies, primarily focusing on gene augmentation-based therapies,. Read More>>

Subscribe to Our Newsletter

For exclusive content regarding the latest trends in the world of Press Release distribution.